Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 30:12:1573080.
doi: 10.3389/fcvm.2025.1573080. eCollection 2025.

Venous thromboembolism prophylaxis practices in hematology/oncology patients admitted to neurological intensive care units

Nada Alsuhebany  1   2   3 , Lama Alfehaid  1   2   3 , Danah Alodhaibi  1 , Madhawi Mahdali  1 , Sumaya Almohareb  1   2   3 , Abdulrahman Alshaya  1   2   3
Affiliations

Venous thromboembolism prophylaxis practices in hematology/oncology patients admitted to neurological intensive care units

Nada Alsuhebany et al. Front Cardiovasc Med. .

Abstract

Objective: Venous thromboembolism (VTE) presents a significant challenge for neurocritically ill patients with cancer due to the combined risks of thrombosis and bleeding. This study aimed to describe VTE prophylaxis practices among this high-risk population.

Methods: This is a retrospective cohort study at a tertiary teaching hospital. Data were obtained for all patients admitted with neurocritical illness with a history of either solid tumors or hematological malignancies. The main outcome was the incidence of bleeding events in the neurocritical care unit (NCCU) using the International Society on Thrombosis and Haemostasis (ISTH) criteria. Other secondary outcomes were the incidence of thrombotic events, NCCU length of stay, and in-hospital mortality.

Results: Out of the 168 patients screened, 43 patients were included, of which 38 patients (88.3%) had solid tumors, and 5 patients (11.6%) had hematologic malignancies. The majority of patients (81.3%) received chemical VTE prophylaxis during hospitalization. The incidence of major bleeding events was reported in 8 patients (21%) with solid tumors and one patient (20%) with hematologic malignancies, with no cases of thrombosis during hospitalization. Compared to the literature, the incidence of major bleeding events in our study is lower than indicated by a previous report on high bleeding risks in similar patient populations. The median duration of hospital stay was five days in the NCCU and 17 days in the hospital, with a 30-day mortality rate of 14%.

Conclusion: Our study highlights the complexity of managing VTE prophylaxis in neurocritically ill cancer patients, emphasizing the need for a careful risk-benefit assessment. The absence of thrombotic events suggests effectiveness; however, bleeding risks warrant caution. These findings underscore the importance of individualized care and highlight the need for further research to refine prophylaxis protocols, thereby ensuring both safety and efficacy in this high-risk group.

Keywords: anticoagulant activity; hematology; neurological; oncology; thrombosis; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowsheet of the study screening and inclusion. Flowchart of patient selection for the study. A total of 168 patients were screened, with 43 patients enrolled. Exclusions (n = 125) were due to not receiving VTE prophylaxis, being younger than 18 years old, or having no history of solid or hematologic.
Figure 2
Figure 2
Incidence of bleeding.
See this image and copyright information in PMC

References

    1. Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. (2018) 2(22):3198–225. 10.1182/bloodadvances.2018022954 - DOI - PMC - PubMed
    1. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association [published correction appears in circulation. 2023 Feb 21;147(8):e622] [published correction appears in circulation. 2023 Jul 25;148(4):e4]. Circulation. (2023) 147(8):e93–621. 10.1161/CIR.0000000000001123 - DOI - PMC - PubMed
    1. Viarasilpa T, Panyavachiraporn N, Jordan J, Marashi SM, van Harn M, Akioyamen NO, et al. Venous thromboembolism in neurocritical care patients. J Intensive Care Med. (2020) 35(11):1226–34. 10.1177/0885066619841547 - DOI - PubMed
    1. Moheet AM, Livesay SL, Abdelhak T, Bleck TP, Human T, Karanjia N, et al. Standards for neurologic critical care units: a statement for healthcare professionals from the neurocritical care society. Neurocrit Care. (2018) 29(2):145–60. 10.1007/s12028-018-0601-1 - DOI - PubMed
    1. Sauro KM, Soo A, Kramer A, Couillard P, Kromm J, Zygun D, et al. Venous thromboembolism prophylaxis in neurocritical care patients: are current practices, best practices? Neurocrit Care. (2019) 30(2):355–63. 10.1007/s12028-018-0614-9 - DOI - PubMed

LinkOut - more resources